Immunity · 2012
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bosma Anneleen, Abdel-Gadir Azza, Isenberg David A, Jury Elizabeth C, Mauri Claudia
Аннотация
B cells perform many immunological functions, including presenting lipid antigen to CD1d-restricted invariant natural killer T (iNKT) cells, known to contribute to maintaining tolerance in autoimmunity. Patients with systemic lupus erythematous (SLE) display dysregulated B cell responses and reduced peripheral iNKT cell frequencies. The significance of these defects and how they relate to SLE pathogenesis remain elusive. We report that B cells are essential for iNKT cell expansion and activation in healthy donors but fail to exert a similar effect in SLE patients. Defective B cell-mediated stimulation of iNKT cells in SLE patients was associated with altered CD1d recycling, a defect recapitulated in B cells from healthy donors after stimulation with interferon-α (IFN-α) and anti-immunoglobulin (Ig). iNKT cell number and function were restored in SLE patients responding to anti-CD20 treatment upon normalization of CD1d expression exclusively in repopulated immature B cells. We propose that healthy B cells are pivotal for iNKT cell homeostasis.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntigen PresentationAntigens, CD1dB-LymphocytesCase-Control StudiesCell DifferentiationCell ProliferationCytokinesFemaleHumansImmunosuppressive AgentsLipidsLupus Erythematosus, SystemicLymphocyte ActivationLymphocyte CountMaleMiddle AgedNatural Killer T-CellsRituximabYoung Adult